U JEDNOM GLAVNOM ISPITIVANJU KOJE JE OBUHVATILO на Английском - Английский перевод

• in one main study involving

Примеры использования U jednom glavnom ispitivanju koje je obuhvatilo на Хорватском языке и их переводы на Английский язык

Lijek Perjeta ispitan je u jednom glavnom ispitivanju koje je obuhvatilo 808 odraslih osoba s prethodno.
Perjeta has been studied in one main study involving 808 adults with previously untreated HER2.

Lijek Ixiaro primijenjen u dvije doze u razmaku od 4 tjedna ispitan je u jednom glavnom ispitivanju koje je obuhvatilo 867 zdravih odraslih osoba.
Ixiaro given as two doses 4 weeks apart has been studied in one main study involving 867 healthy adults.

Zutectra je ispitivan u jednom glavnom ispitivanju koje je obuhvatilo 30 odraslih osoba koje su imale transplantaciju jetre.
Zutectra has been studied in one main study involving 30 adults who had undergone liver transplants.

Ratiograstim je uspoređen s lijekom Neupogen i placebom(lažnim liječenjem) u jednom glavnom ispitivanju koje je obuhvatilo 348 bolesnika oboljelih od raka dojke.
Ratiograstim was compared with Neupogen and with placebo(a dummy treatment) in one main study involving 348 patients with breast cancer.

Velphoro je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 1059 odraslih osoba s kroničnom bolesti bubrega i hiperfosfatemijom.
Velphoro has been studied in one main study involving 1,059 adults with long-term kidney disease and hyperphosphataemia.

Za liječenje osteoporoze u muškaraca, lijek Prolia uspoređen je s placebom u jednom glavnom ispitivanju koje je obuhvatilo 242 muškarca s osteoporozom.
For the treatment of osteoporosis in men, Prolia has been compared with placebo in one main study involving 242 men with osteoporosis.

Strensiq se ispitivao u jednom glavnom ispitivanju koje je obuhvatilo 13 djece u dobi od šest do 12 godina.
Strensiq has been studied in one main study in 13 children between 6 and 12 years of age.

U pogledu prevencije premalignih lezija ili raka cerviksa, cjepivo Cervarix ispitano je u jednom glavnom ispitivanju koje je obuhvatilo gotovo 19 000 žena u dobi između 15 i 25 godina.
For the prevention of precancerous lesions or cancer of the cervix, Cervarix has been investigated in one main study involving almost 19,000 women aged between 15 and 25 years.

Perjeta je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 808 odraslih osoba s prethodno neliječenim metastatskim rakom dojke HER2 pozitivnim.
Perjeta has been studied in one main study involving 808 adults with previously untreated HER2- positive metastatic breast cancer.

ChondroCelect je uspoređen s mikrofrakturom(tipom kirurškog zahvata koji se koristi za liječenje oštećenja hrskavice) u jednom glavnom ispitivanju koje je obuhvatilo 118 odraslih osoba sa simptomima koji su uzrokovali oštećenja u njihovim hrskavicama koljena.
ChondroCelect was compared with microfracture(a type of surgery used to treat defects in cartilage) in one main study involving 118 adult patients with symptoms caused by defects in their knee cartilage.

Lijek Vitekta ispitan je u jednom glavnom ispitivanju koje je obuhvatilo 712 bolesnika s infekcijomHIV- 1 koji nisu prethodno liječeni inhibitorom integraze.
Vitekta has been investigated in one main study involving 712 patients with HIV-1 who had not been treated before with an integrase inhibitor.

Epoetin Alfa Hexal ubrizgan u venu uspoređen je s referentnim lijekom u jednom glavnom ispitivanju, koje je obuhvatilo 479 bolesnika s anemijom uzrokovanom problemima s bubrezima.
Epoetin Alfa Hexal, injected into a vein, was compared with the reference medicine in one main study involving 479 patients with anaemia caused by kidney problems.

Hemangiol je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 460 djece u dobi od pet tjedana do pet mjeseci na početku liječenja i koji su oboljeli od proliferirajućeg infantilnog hemangioma koji zahtjeva sistemsku terapiju.
Hemangiol was investigated in one main study involving 460 children aged from five weeks to five months at the start of treatment and who had proliferative infantile haemangioma that required systemic therapy.

Za liječenje gubitka kosti u muškaraca koji primaju terapiju protiv raka prostate, lijek Prolia uspoređen je s placebom u jednom glavnom ispitivanju koje je obuhvatilo 1 468 muškaraca koji su primali terapiju protiv raka prostate i kod kojih je postojao povećani rizik od frakture.
For the treatment of bone loss in men receiving treatment for prostate cancer, Prolia has also been compared with placebo in one main study involving 1,468 men receiving treatment for prostate cancer who were at an increased risk of fracture.

Dacogen je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 485 odraslih osoba s novodijagnosticiranim AML-om koji nisu bili kandidati za standardnu indukcijsku kemoterapiju.
Dacogen has been studied in one main study involving 485 adults, who were newly diagnosed with AML but were not eligible for standard induction chemotherapy.

U slučaju neradiografskog aksijalnog spondiloartritisa bez radiografskih dokaza, lijek Simponi uspoređen je s placebom tijekom 16 tjedana u jednom glavnom ispitivanju koje je obuhvatilo 198 bolesnika koji su imali bolest bez jasnog dokaza ankiloznog spondilitisa, ali sa znakovima upale, te nisu primjereno odgovorili na terapiju NSAID-ovima.
For non-radiographic axial spondyloarthritis, Simponi was compared with placebo over 16 weeks in one main study involving 198 patients who had the disease without evidence of ankylosing spondylitis but with signs of inflammation and who had not responded adequately to treatment with NSAIDs.

Mekinist je ispitivan u jednom glavnom ispitivanju koje je obuhvatilo 322 bolesnika s melanomom koji se proširio na druge dijelove tijela ili se nije mogao ukloniti kirurškim zahvatom te čiji je melanom imao mutaciju BRAF V600.
Mekinist has been studied in one main study involving 322 patients with melanoma that had spread to other parts of the body or could not be surgically removed, and whose melanoma had the BRAF V600 mutation.

Ubrizgan u venu uspoređen je s referentnim lijekom u jednom glavnom ispitivanju, koje je obuhvatilo 479 bolesnika s anemijom uzrokovanom problemima s bubrezima.
Injected into a vein, was compared with the reference medicine in one main study involving 479 patients with anaemia caused by kidney problems.

U jednom glavnom ispitivanju koje je obuhvatilo 665 bolesnika s naprednim stadijem gastričnog karcinoma ili karcinomom gastroezofagealnog spoja, čije se stanje pogoršalo unatoč terapiji lijekovima koji sadrže platinu i fluoropirimidin, bolesnici liječeni lijekom Cyramza i paklitakselom živjeli su prosječno znatno duže u odnosu na bolesnike liječene paklitakselom i placebom( prividnim liječenjem): 9, 6 mjeseci u odnosu na 7, 4 mjeseca.
In one main study involving 665 patients with advanced gastric or gastro-oesophageal junction cancer which worsened despite treatment with medicines containing platinum and fluoropyrimidine, those treated with Cyramza and paclitaxel lived significantly longer on average than patients treated with paclitaxel and placebo(a dummy treatment): 9.6 months versus 7.4 months respectively.

Dokazano je da lijek Respreeza usporava oštećenje pluća u jednom glavnom ispitivanju koje je obuhvatilo 180 bolesnika s oštećenjem pluća uslijed deficijencije inhibitora alfa1-proteinaze.
Respreeza has been shown to slow down lung damage in one main study involving 180 patients with lung damage due to alpha1-proteinase inhibitor deficiency.

Translarna je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 174 bolesnika oboljelih od Duchenneove mišićne distrofije koji mogu hodati, u kojem su dvije doze lijeka Translarna(40 mg/kg dnevno i 80 mg/kg dnevno) uspoređene s placebom prividnim liječenjem.
Translarna has been studied in one main study involving 174 patients with Duchenne muscular dystrophy who were able to walk, where two doses of Translarna(40 mg/kg daily and 80 mg/kg daily) were compared with placebo a dummy treatment.

Emadine je uspoređen s levokabastinom(drugim antihistaminom) u jednom glavnom ispitivanju koje je obuhvatilo 222 bolesnika sa sezonskim konjuktivitisom u dobi od četiri godine i više.
Emadine has been compared with levocabastine(another antihistamine) in one main study involving 222 patients with seasonal conjunctivitis aged four years and over.

Neuraceq je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 216 dobrovoljaca podijeljenih u dvije grupe: grupu zdravih mladih ljudi i grupu bolesnika koji su se bližili završetku svojih života, koji su dali svoju suglasnost za autopsije nakon što umru; 41 dobrovoljac(10 zdravih mladih ljudi i 31 bolesnik) završilo je ispitivanje i bili su uključeni u rezultate.
Neuraceq has been investigated in one main study involving 216 volunteers divided into two groups: a group of healthy young people and a group of patients nearing the end of their lives who had consented to autopsies when they died; 41 volunteers(10 healthy young people and 31 patients) completed the study and were included in the results.

Ovaleap je uspoređen s lijekom GONAL-f u jednom glavnom ispitivanju koje je obuhvatilo 299 žena, koje su bile podvrgnute liječenju neplodnosti.
Ovaleap has been compared with GONAL-f in one main study involving 299 women undergoing fertility treatment.

Koristi lijeka Ikervis koje su utvrđene u jednom glavnom ispitivanju koje je obuhvatilo 246 bolesnika s ozbiljnom bolesti suhoga oka, pri čemu je Ikervis uspoređen s punilom ista formula kapljica za oči, no bez bilo kakve djelatne tvari.
The benefits of Ikervis have been shown in one main study involving 246 patients with severe dry eye disease, where Ikervis was compared with the vehicle the same eye drop formula but without any active substance.

Kengrexal je uspoređen s klopidogrelom koji se uzima peroralno u jednom glavnom ispitivanju koje je obuhvatilo više od 11 odraslih osoba s koronarnom arterijskom bolešću, koji su podvrgnuti PCI-u.
Kengrexal was compared with clopidogrel taken by mouth in one main study involving over 11,000 adults with coronary artery disease who were undergoing PCI.

Koristi lijeka Farydak dokazane su u jednom glavnom ispitivanju koje je obuhvatilo 768 bolesnika s multiplim mijelomom koji se pogoršao nakon prethodnih terapija.
The benefits of Farydak have been shown in one main study involving 768 patients with multiple myeloma that had come back after previous treatments.

Četiri doze lijeka Adcirca(2, 5, 10, 20 i 40 mg jednom na dan) uspoređene su s placebom(prividnim liječenjem) u jednom glavnom ispitivanju koje je obuhvatilo 406 bolesnika s PAH-om, većina od kojih je imala klasu II ili kjlasu III bolesti, u slučaju kojih uzrok nije bio poznat ili su uzrokovane kolagenskom vaskularnom bolesti.
Four doses of Adcirca(2.5, 10, 20 and 40 mg once a day) have been compared with placebo(a dummy treatment) in one main study involving 406 patients with PAH, most of whom had class II or class III disease that was of unknown cause or caused by collagen vascular disease.

Djelotvornost cjepiva procijenjena je u jednom glavnom ispitivanju koje je obuhvatilo 2 654 odraslih osoba, od kojih je otprilike polovica bila starije dobi stariji od 60 godina.
The vaccine's effectiveness was assessed in one main study involving 2,654 adults, around half of whom were elderly over 60 years of age.

Bemfola je uspoređen s lijekom GONAL-f u jednom glavnom ispitivanju koje je obuhvatilo 372 žena koje su bile podvrgnute tehnikama potpomognute oplodnje.
Bemfola was compared with GONAL-f in one main study involving 372 women who were undergoing assisted reproductive techniques.